Expressions and Clinical Significance of P-gp, GST-π and C-erbB-2 in Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

SUN Hao ¹ , YU Xiao dong. ²

1.Department of General Surgery, The Third People’s Hospital of Chongqing, Chongqing 400014, China;;
2.Department of Pathology, The Third People’s Hospital of Chongqing, Chongqing 400014, ChinaCorresponding Author: SUN Hao, E-mail: sunhao68@sina.com;

Corresponding author：

Keywords：

Breast cancer; Permeability-glycoprotein; Placental glutathione-s-transferase-π; Human epidermal growth factor receptor 2; Prognosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the relationship between the expressions of P-gp, GST-π and C-erbB-2 and clinicopathologic characteristics as well as prognosis in breast cancer. Methods The expressions of P-gp， GST-π and C-erbB-2 were detected by immunohistochemistry in 48 cases of breast cancer, and histopathologic characteristics as well as 5-year survival rate of these cases were analyzed. Results There was no significant difference in the expressions of P-gp and GST-π with age, histologic grade, number of lymph node metastasis and TNM stage of breast cancer ( P ＞ 0.05). There was significant difference in expression of C-erbB-2 with histologic grade, number of lymph node metastasis and TNM stage of breast cancer （ P ＜ 0.05）. Positive rate of P-gp expression in breast cancer with positive C-erbB-2 expression was remarkably higher than that in breast cancer with negative C-erbB-2 expression ( P ＜ 0.05) . Positive rate of GST-π and C-erbB-2 expression in survivals within 5 years was remarkably lower than that in deaths within 5 years ( P ＜ 0.01). Conclusion P-gp participates primary drug-resistance mechanism of breast cancer. The possibility of primary drug-resistance is higher in breast cancer with positive C-erbB-2 expression. The expression of C-erbB-2 helps to evaluate prognosis and the result of treatment in breast cancer.

Citation： SUN Hao,YU Xiao dong.. Expressions and Clinical Significance of P-gp, GST-π and C-erbB-2 in Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(1): 56-59. doi: Copy

1.	Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter [Ｊ] . Annu Rev Biochem, 1993; 62(4)：385.
2.	Coles B, KettererB. The role of glutathione and glutathione transferase in chemical carcinogenesis [Ｊ] . Crit Rev Biochem Mol Biol, 1990; 25(1)： 47.
3.	刘复生，李晓，张询，等. 乳腺癌的组织学分级与预后 [Ｊ] . 中华病理学杂志， 1993； 22（1）：36.
4.	李树玲主编. 乳腺肿瘤学 [M] . 第1版. 北京：科学技术文献出版社, 2000： 392~396.
5.	孙希印，周晓秋，高虹，等. P-gp、 GST-π、 TopoⅡ、 p53在乳腺癌中的表达及相关性 [Ｊ] . 中国现代普通外科进展， 2007； 10（3）：224.
6.	吴名耀，李乔山，吴贤英，等. EGR-1、 C-erbB-2、 ER、 PR在乳腺癌中的表达及其相互关系 [Ｊ] . 临床实验与病理学杂志， 2000； 16(5)： 388.
7.	吉兆宁，刘国卿. P-糖蛋白介导多药耐药性逆转 [Ｊ] . 中国临床药理学和治疗学， 2002； 7（3）：269.
8.	薛军，支学军，屈明，等. 胃癌及食管癌中肿瘤耐药标志物P-糖蛋白和谷胱甘肽转移酶表达的研究 [Ｊ] . 中国普外基础与临床杂志， 2002； 9（5）：F002.
9.	Izquierdo MA, Scheffer GL, Flens MJ, et al . Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticarcinoma drugs [Ｊ] . Cytotechnology, 1996; 19(3)：191.
10.	Morceau F, Duvoix A, Delhalle S, et al . Regulation of glutathione-S-transferase P1-1 gene expression by NF-KappaB in tumor necrosis factor alpha-treated K562 leukemia cells [Ｊ] . Biochem Pharmacol, 2004; 67(7)： 1227.
11.	Toffoli G, Viel A, Tumiotto L, et al . Expression of glutathione-S-transferase-π in human tumours [Ｊ] . Eur J carcinoma, 1992; 28A(8-9)： 1441.
12.	Benderra Z, Morjani H, Trussardi A, et al . Evidence for functional discrimination between leukemic cells overexpressing multidrug-resistance associated protein and P-glycoprotein [Ｊ] . Adv Exp Med Biol, 1999; 457(5)：151.
13.	范伟，杨金巧，伍晓汀. 乳腺浸润性导管癌中PS2和GSTπ的表达及临床意义 [Ｊ] . 中国普外基础与临床杂志， 2004； 11（1）：14.
14.	胡伟国，张保宁. Her-2的研究进展与乳腺癌 [Ｊ] . 肿瘤学杂志， 2002； 8（6）：347.
15.	孙治君，周鑫，姚榛祥，等. EGFR、 C-erbB2和PCNA在多原发乳腺癌组织的表达及意义 [Ｊ] . 重庆医科大学学报， 2003； 28(2)： 156.
16.	Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract [Ｊ] . carcinoma Invest, 2001; 19(5)：544.
17.	刘胜春，吴凯南，厉红元，等. 血管生成与p53、 C-erbB-2癌基因蛋白在乳腺非典型增生及癌变过程中的相关性 [Ｊ] . 中国普外基础与临床杂志， 2001； 8（5）：304.
18.	Stewart MC, Kadlcek RM, Robbins PD, et al . Expression and activity of the CDK inhibitor p57 Kip2 in chondrocytes undergoing hypertrophic differentiation [Ｊ] . J Bone Miner Res, 2004; 19(1)：123.
19.	Bhatavdekar JM, Parel DD, Shah NG, et al . Prognostic significance of immunohismchemically localized biomarkers in stage Ⅱ and stage Ⅲ breast carcinoma: a multivariate analysis [Ｊ] . Ann Surg Oncol, 2000; 7(4)： 305.

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter [Ｊ] . Annu Rev Biochem, 1993; 62(4)：385.
2. Coles B, KettererB. The role of glutathione and glutathione transferase in chemical carcinogenesis [Ｊ] . Crit Rev Biochem Mol Biol, 1990; 25(1)： 47.
3. 刘复生，李晓，张询，等. 乳腺癌的组织学分级与预后 [Ｊ] . 中华病理学杂志， 1993； 22（1）：36.
4. 李树玲主编. 乳腺肿瘤学 [M] . 第1版. 北京：科学技术文献出版社, 2000： 392~396.
5. 孙希印，周晓秋，高虹，等. P-gp、 GST-π、 TopoⅡ、 p53在乳腺癌中的表达及相关性 [Ｊ] . 中国现代普通外科进展， 2007； 10（3）：224.
6. 吴名耀，李乔山，吴贤英，等. EGR-1、 C-erbB-2、 ER、 PR在乳腺癌中的表达及其相互关系 [Ｊ] . 临床实验与病理学杂志， 2000； 16(5)： 388.
7. 吉兆宁，刘国卿. P-糖蛋白介导多药耐药性逆转 [Ｊ] . 中国临床药理学和治疗学， 2002； 7（3）：269.
8. 薛军，支学军，屈明，等. 胃癌及食管癌中肿瘤耐药标志物P-糖蛋白和谷胱甘肽转移酶表达的研究 [Ｊ] . 中国普外基础与临床杂志， 2002； 9（5）：F002.
9. Izquierdo MA, Scheffer GL, Flens MJ, et al . Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticarcinoma drugs [Ｊ] . Cytotechnology, 1996; 19(3)：191.
10. Morceau F, Duvoix A, Delhalle S, et al . Regulation of glutathione-S-transferase P1-1 gene expression by NF-KappaB in tumor necrosis factor alpha-treated K562 leukemia cells [Ｊ] . Biochem Pharmacol, 2004; 67(7)： 1227.
11. Toffoli G, Viel A, Tumiotto L, et al . Expression of glutathione-S-transferase-π in human tumours [Ｊ] . Eur J carcinoma, 1992; 28A(8-9)： 1441.
12. Benderra Z, Morjani H, Trussardi A, et al . Evidence for functional discrimination between leukemic cells overexpressing multidrug-resistance associated protein and P-glycoprotein [Ｊ] . Adv Exp Med Biol, 1999; 457(5)：151.
13. 范伟，杨金巧，伍晓汀. 乳腺浸润性导管癌中PS2和GSTπ的表达及临床意义 [Ｊ] . 中国普外基础与临床杂志， 2004； 11（1）：14.
14. 胡伟国，张保宁. Her-2的研究进展与乳腺癌 [Ｊ] . 肿瘤学杂志， 2002； 8（6）：347.
15. 孙治君，周鑫，姚榛祥，等. EGFR、 C-erbB2和PCNA在多原发乳腺癌组织的表达及意义 [Ｊ] . 重庆医科大学学报， 2003； 28(2)： 156.
16. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract [Ｊ] . carcinoma Invest, 2001; 19(5)：544.
17. 刘胜春，吴凯南，厉红元，等. 血管生成与p53、 C-erbB-2癌基因蛋白在乳腺非典型增生及癌变过程中的相关性 [Ｊ] . 中国普外基础与临床杂志， 2001； 8（5）：304.
18. Stewart MC, Kadlcek RM, Robbins PD, et al . Expression and activity of the CDK inhibitor p57 Kip2 in chondrocytes undergoing hypertrophic differentiation [Ｊ] . J Bone Miner Res, 2004; 19(1)：123.
19. Bhatavdekar JM, Parel DD, Shah NG, et al . Prognostic significance of immunohismchemically localized biomarkers in stage Ⅱ and stage Ⅲ breast carcinoma: a multivariate analysis [Ｊ] . Ann Surg Oncol, 2000; 7(4)： 305.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions and Clinical Significance of P-gp, GST-π and C-erbB-2 in Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content